Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001031309 | SCV001194615 | pathogenic | Pulmonary hypertension, primary, 1 | 2019-12-16 | criteria provided, single submitter | clinical testing | This variant is an in-frame deletion of the genomic region encompassing exon 3 of the BMPR2 gene. It preserves the integrity of the reading frame. This variant has been observed in individual(s) with pulmonary arterial hypertension (PMID: 28388887, 16728714, 21801371). This variant disrupts the p.Cys99 amino acid residue in BMPR2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 19555857, 30578397, Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Labcorp Genetics |
RCV001383551 | SCV001582717 | pathogenic | Primary pulmonary hypertension | 2020-10-18 | criteria provided, single submitter | clinical testing | This variant is an in-frame deletion of the genomic region encompassing exon 3 of the BMPR2 gene. It preserves the integrity of the reading frame. This variant has been observed in individual(s) with pulmonary arterial hypertension (PMID: 28388887, 16728714, 21801371). This variant disrupts the p.Cys99 amino acid residue in BMPR2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 19555857, 30578397, Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |